Floatz logo

Orelabrutinib

Marginal Zone Lymphoma

Henan Cancer HospitalSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

99 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
University of Miami
Phase 2BBB
Vincristine Sulfate
Mayo Clinic
Phase 2BBB
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 2BBB
Nivestim
Fred Hutchinson Cancer Center
Phase 2BBB
Rituximab
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Orelabrutinib is also rated in:

primary central nervous system lymphomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 3
68 / 100
View asset →
mantle cell lymphomaActive
B
Indicative · Phase 3
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →